Bristol Myers Squibb Reports Patient Death in Clinical CAR-T Trial for Autoimmune Disease

When CAR-T cell therapies were first deployed against aggressive blood cancers, severe immune side effects were accepted as a necessary trade-off for survival. But as Bristol Myers Squibb tests that same technology against multiple sclerosis—a debilitating but non-fatal condition—a newly disclosed patient death is shifting how researchers weigh those risks.[2]

The pharmaceutical company confirmed Friday that a patient participating in its Phase 1 Breakfree-2 trial died from septic pneumonia. The patient, who had highly active relapsing multiple sclerosis, passed away 44 days after receiving an infusion of the experimental CAR-T therapy zolacabtagene autoleucel, or zola-cel.[2][4]

The disclosure highlights the tension at the frontier of autoimmune research. While early data shows the therapy can completely halt disease progression in some patients, the fatal outcome underscores the profound physical toll of reprogramming a patient's immune system.[4][5]

A cascading immune response

The fatal event followed a complex cascade of neurological and immune complications. After receiving the zola-cel infusion, the patient developed late-onset motor symptoms that did not fit the typical profile of immune effector cell-associated neurotoxicity syndrome, a known CAR-T side effect.[2][3]

Clinicians initially attempted to manage the symptoms with intermittent corticosteroids and intravenous immunoglobulin, which are standard protocols for neurotoxicity. When those interventions failed to resolve the motor issues, the medical team administered high-dose cyclophosphamide, a powerful immunosuppressant designed to halt the runaway immune response.[3][4]

The patient subsequently developed septic pneumonia, a severe lung infection complicated by a systemic inflammatory response. They died the following day, 44 days after the initial infusion of the engineered cells.[2][4]

Bristol Myers Squibb noted in its disclosure that the fatality was an isolated event. "No additional deaths have been reported across all zola-cel programs in autoimmune diseases," the company stated, referencing a broader safety database that includes 190 patients treated in Phase 1 studies.[2]

The broader safety data from the Breakfree-2 trial illustrates how common immune reactions are with this class of therapy. Among the 66 patients evaluated, 42.4 percent experienced cytokine release syndrome, a systemic inflammatory response triggered by the engineered T-cells.[2][3]

Most of these reactions were manageable without intensive intervention. The data showed that 36.4 percent of cases were Grade 1 and 6.1 percent were Grade 2, with symptoms typically resolving in a median of two days.[2][4]

However, severe events remain a persistent threat for trial participants. One patient with progressive multiple sclerosis suffered a life-threatening Grade 4 neurotoxicity event, which required treatment with corticosteroids and the arthritis biologic anakinra before resolving after four days.[2][3]

The efficacy calculation

Despite the severe risks, the clinical appeal of CAR-T therapy in autoimmune disease stems from its unprecedented efficacy. The treatment aims to perform a complete immune reset by depleting the B-cells responsible for attacking the patient's own nervous system.[4][5]

The interim results from the Breakfree-2 study demonstrate exactly why researchers continue to pursue the approach despite the known dangers. At the trial's second dose level, all 60 treated patients remained entirely off standard disease-modifying therapies at their last clinical follow-up.[3][4]

For a disease characterized by relentless progression and frequent relapses, achieving total disease stability without ongoing medication is a landmark result. Nine of those patients have maintained that stability for more than 12 months, suggesting the immune reset may be durable.[2][4]

Efficacy data evaluated at the 26-week mark further reinforced the therapy's potential. Six out of seven patients with highly active relapsing disease showed no evidence of disease activity, while eight patients saw their disability status either stabilize or improve.[3]

Re-evaluating the risk threshold

The death in the Bristol Myers Squibb trial is not an isolated incident in the autoimmune CAR-T space. In August 2026, Novartis suspended multiple studies of its own CAR-T candidate, rapcabtagene autoleucel, following the deaths of three patients.[2]

Those Novartis fatalities were linked to immune effector cell-associated hemophagocytic syndrome, a severe hyperinflammatory condition. Around the same time, Bristol Myers Squibb voluntarily paused several of its own autoimmune trials after identifying unspecified safety signals.[2]

For patients evaluating experimental treatments, these outcomes clarify the stakes. CAR-T therapy involves extracting a patient's own T-cells, engineering them in a laboratory to attack specific CD19-expressing B-cells, and reinfusing them into the bloodstream—a complex biological process that inherently carries a risk of catastrophic immune overreaction.[2][5]

While oncologists routinely accept a 1 to 2 percent mortality risk for therapies that cure terminal cancers, neurologists face a different calculus. Multiple sclerosis significantly impairs quality of life, but patients can often live for decades with standard disease-modifying drugs.[2][5]

The current standard of care for multiple sclerosis involves continuous immune suppression through regular infusions or daily oral medications. While these drugs slow disease progression, they leave patients permanently vulnerable to routine infections, require lifelong adherence, and rarely reverse existing neurological damage. CAR-T therapy promises to replace that chronic management with a single, definitive intervention.[4][5]

Regulators and clinical trial review boards must now determine whether the possibility of a permanent cure justifies the immediate risk of fatal immune complications. That assessment will likely restrict early CAR-T access to patients who have exhausted all conventional treatment options.[2][5]